Clinical Trial Update: A Trial of HRS5580 in Prevention of Postoperative Nausea and Vomiting of Adults [Phase 2]

View source ↗

Summary

A Phase 2 study of HRS5580 in preventing postoperative nausea and vomiting in adults has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Postoperative Nausea and Vomiting

Drugs mentioned

• HRS5580

Snippet

Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd. | Conditions: Preventing of Postoperative Nausea and Vomiting in Adults | Phase 2 | Status: COMPLETED